---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-003288"
form_type: "8-K"
ticker: "PAYS"
cik: "0001496443"
company_name: "Paysign, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:01:32.638927+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Paysign Q1 2025 revenue up 41% to $18.6M, net income $2.59M; raises full-year guidance

## Summary
- Total revenues $18.60M (+41% YoY); net income $2.59M ($0.05 diluted EPS) vs $309K ($0.01) in Q1 2024.
- Adjusted EBITDA $4.96M (+193.3%); pharma patient affordability revenue surged 260.8% to 46.3% of revenue.
- Added 14 net patient affordability programs (total 90); plasma revenue fell 9.2%, center count 484.
- FY2025 guidance raised: revenue $72-74M, net income $6-7M ($0.10-$0.12 EPS), Adj. EBITDA $16-17M.
- Q2 2025 revenue guided $18.5-19.0M; Gamma acquisition expected to generate $4-5M annual cash cost savings.

## SEC filing metadata
- accession: 0001683168-25-003288
- form_type: 8-K
- ticker: PAYS
- cik: 0001496443
- company_name: Paysign, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1496443/000168316825003288/0001683168-25-003288-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1496443/000168316825003288/paysign_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-003288
- JSON: https://secwatch.observer/filing/0001683168-25-003288.json
- Plain text: https://secwatch.observer/filing/0001683168-25-003288.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.